Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-6172
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
INO-6172 is a DNA-launched nanoparticle (DLNP) vaccine candidate developed by Inovio Pharmaceuticals for the prevention and treatment of HIV-1 infections. The vaccine utilizes Inovio's proprietary DNA technology to encode a self-assembling nanoparticle displaying the GT8 immunogen, which is a germline-targeting HIV-1 envelope protein fragment, alongside interleukin-12 (IL-12) as a genetic adjuvant. This approach is designed to provide high and maintained levels of antibody responses, including broadly neutralizing antibodies (bNAbs), while simultaneously generating robust T cell responses. INO-6172 is currently being evaluated in Phase 1 clinical trials, such as HVTN 305 (NCT05781542), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), and is typically administered via intradermal injection.
- Other names
- DNA-launched nanoparticle HIV vaccineDLNP-GT8DLNP-GT-8DLNP-GT 8
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on INO-6172.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-6172.